312 results on '"Mezzaroma, Ivano"'
Search Results
302. Potential benefit of dolutegravir once daily: efficacy and safety.
- Author
-
Fantauzzi A, Turriziani O, and Mezzaroma I
- Abstract
The viral integrase enzyme has recently emerged as a primary alternative target to block HIV-1 replication, and integrase inhibitors are considered a pivotal new class of antiretroviral drugs. Dolutegravir is an investigational next-generation integrase inhibitor showing some novel and intriguing characteristics, ie, it has a favorable pharmacokinetic profile with a prolonged intracellular half-life, rendering feasible once-daily dosing without the need for ritonavir boosting and without regard to meals. Moreover, dolutegravir is primarily metabolized via uridine diphosphate glucuronosyltranferase 1A1, with a minor component of the cytochrome P450 3A4 isoform, thereby limiting drug-drug interactions. Furthermore, its metabolic profile enables coadministration with most of the other available antiretroviral agents without dose adjustment. Recent findings also demonstrate that dolutegravir has significant activity against HIV-1 isolates with resistance mutations associated with raltegravir and/or elvitegravir. The attributes of once-daily administration and the potential to treat integrase inhibitor-resistant viruses make dolutegravir an interesting and promising investigational drug. In this review, the main concerns about the efficacy and safety of dolutegravir as well as its resistance profile are explored by analysis of currently available data from preclinical and clinical studies.
- Published
- 2013
- Full Text
- View/download PDF
303. Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease.
- Author
-
Esposito A, Floridia M, d'Ettorre G, Pastori D, Fantauzzi A, Massetti P, Ceccarelli G, Ajassa C, Vullo V, and Mezzaroma I
- Subjects
- Adult, Alkynes, Benzoxazines therapeutic use, CD4 Lymphocyte Count, CD4-Positive T-Lymphocytes immunology, Cyclopropanes, Female, HIV Infections immunology, HIV Protease Inhibitors therapeutic use, HIV-1 drug effects, Humans, Male, Middle Aged, RNA, Viral blood, Retrospective Studies, Reverse Transcriptase Inhibitors therapeutic use, Ritonavir therapeutic use, Viral Load, Antiretroviral Therapy, Highly Active, HIV Infections drug therapy
- Abstract
Background: The optimal therapeutic strategies for patients presenting with advanced disease at HIV-1 diagnosis are as yet incompletely defined., Methods: All patients presenting at two outpatient clinics in 2000-2009 with an AIDS-defining clinical condition or a CD4+ T cell count < 200/μL at HIV-1 diagnosis were analyzed for the presence of combined immunovirological response, defined by the concomitant presence of an absolute number of CD4+ T cells > 200 cells/μL and a plasma HIV-1 RNA copy number < 50/mL after 12 months of HAART., Results: Among 102 evaluable patients, first-line regimens were protease inhibitors [PI]-based in 78 cases (77%) and efavirenz-based in 24 cases (23%). The overall response rate was 65% (95% CI: 55-74), with no differences by gender, age, nationality, route of transmission, hepatitis virus coinfections, presence of AIDS-defining clinical events, baseline HIV-1 viral load, or type of regimen (response rates with PI-based and efavirenz-based therapy: 63% and 71%, respectively, p = 0.474). Response rate was significantly better with higher baseline CD4+ T cell counts (78% with CD4+ ≥ 100/μL, compared to 50% with CD4+ < 100/μL; odds ratio: 3.5; 95% CI: 1.49-8.23, p = 0.003). Median time on first-line antiretroviral therapy was 24 months (interquartile range: 12-48). Switch to a second line treatment occurred in 57% of patients, mainly for simplification (57%), and was significantly more common with PI-based regimens [adjusted hazard ratios (AHR) with respect to efavirenz-based regimens: 3.88 for unboosted PIs (95% CI: 1.40-10.7, p = 0.009) and 4.21 for ritonavir-boosted PI (95% CI 1.7-10.4, p = 0.002)] and in older subjects (≥ 50 years) (AHR: 1.83; 95% CI: 1.02-3.31, p = 0.044). Overall mortality was low (3% after a median follow up of 48 months)., Conclusions: Our data indicate that a favorable immunovirological response is possible in the majority of naive patients presenting at HIV-1 diagnosis with AIDS or low CD4+ T cell counts, and confirm that starting HAART with a more compromised immune system may be associated with a delayed and sometimes partial immune recovery. Simpler regimens may be preferable in this particular population.
- Published
- 2011
- Full Text
- View/download PDF
304. Mutational resistance pattern of HIV type 1 in CD14+ monocytes, CD4+ T cells, and plasma from treated patients.
- Author
-
Turriziani O, Boni A, Falasca F, Graziano F, Bucci M, D'Ettorre G, Fantauzzi A, Paoletti F, Massetti AP, Mezzaroma I, and Antonelli G
- Subjects
- Genotype, HIV Protease genetics, HIV Reverse Transcriptase genetics, HIV-1 genetics, HIV-1 isolation & purification, Humans, Lipopolysaccharide Receptors analysis, Monocytes chemistry, Sequence Analysis, DNA, CD4-Positive T-Lymphocytes virology, Drug Resistance, Viral, HIV Infections virology, HIV-1 drug effects, Monocytes virology, Mutation, Missense, Plasma virology
- Abstract
It is necessary to understand the molecular nature of the virus population that persists in cellular reservoirs. To achieve this we planned to characterize the patterns of resistance of HIV-1 in CD14(+) monocytes, CD4(+) T cells, and plasma. Blood samples were collected from 42 patients treated for HIV: 32 were in virological failure and in 10 viremia was undetectable. CD14(+) and CD4(+) T cells were isolated using magnetic beads. Genotyping of the reverse transcriptase and protease gene of HIV-1 was undertaken using the fluorescent dideoxy-terminator method. Of the 32 patients in virological failure, 24 (75%) had resistance mutations in at least one compartment. The numbers and types of mutations from monocytes were the same as those detected in both CD4(+) T cell-associated virus and plasma in only 8% whereas in 71% monocytes exhibited a different mutation pattern. In 21% of patients, the profile of drug-resistant mutations in the virus from blood monocytes was identical to that in plasma but differed from that in CD4. In the 71% of patients with virological suppression, the genotypic resistance pattern differed between monocytes and CD4(+) T cells. Circulating monocytes may harbor a viral dominant population different from those viruses circulating in blood and archived in CD4(+) T cells. Hence, monocytes and other cellular reservoirs might serve as an indirect source of a drug-resistant viral variant.
- Published
- 2010
- Full Text
- View/download PDF
305. Lithiasis of semicircular canals and parotid glands: unusual stones deposition in atazanavir-treated individuals.
- Author
-
Pastori D, Esposito A, Cagliuso M, Conti V, and Mezzaroma I
- Subjects
- Aged, Atazanavir Sulfate, Female, HIV Infections drug therapy, Humans, Lithiasis diagnostic imaging, Male, Middle Aged, Radiography, Treatment Outcome, Anti-HIV Agents adverse effects, Labyrinth Diseases chemically induced, Lithiasis chemically induced, Oligopeptides adverse effects, Parotid Diseases chemically induced, Pyridines adverse effects, Semicircular Canals
- Published
- 2009
- Full Text
- View/download PDF
306. [Immunorecovery after prolonged HIV-related immunosuppression: opportunities of the new antiretroviral classes].
- Author
-
Esposito A, Leti W, Fantauzzi A, Pastori D, Isgro A, Aiuti F, and Mezzaroma I
- Subjects
- AIDS-Related Opportunistic Infections drug therapy, Anti-HIV Agents classification, Anti-HIV Agents pharmacology, CD4-Positive T-Lymphocytes classification, CD4-Positive T-Lymphocytes immunology, Cyclohexanes administration & dosage, Cyclohexanes therapeutic use, Darunavir, Drug Resistance, Multiple, Viral, Drug Therapy, Combination, HIV Infections drug therapy, HIV Protease Inhibitors administration & dosage, HIV Protease Inhibitors therapeutic use, HIV-1, Humans, Immunocompetence, Interleukin-2 administration & dosage, Interleukin-2 therapeutic use, Male, Maraviroc, Middle Aged, Reverse Transcriptase Inhibitors administration & dosage, Reverse Transcriptase Inhibitors therapeutic use, Sulfonamides administration & dosage, Sulfonamides therapeutic use, T-Lymphocyte Subsets immunology, Triazoles administration & dosage, Triazoles therapeutic use, Viral Load, Anti-HIV Agents therapeutic use, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, HIV Infections immunology
- Abstract
Treatment of multi-drug experienced patients is an important concern in the management of HIV-1 disease, partially solved by the availability of new drugs acting at different phases of viral replication. Immune recovery during cART is linked both to the activity of antiviral drugs, as well as to the regenerative capability of thymus and bone marrow. We report a patient with a 22-year-old HIV-1 disease and an AIDS diagnosis for 15 years, with extensive resistance to all antiretroviral drugs, who never had treatment interruption, except for short spells due to adverse effects. This decision was supported by both findings elsewhere that interruptions of cART in experienced patients with advanced disease are strongly associated with more rapid disease progression and by our evaluation of his bone marrow activity. The colony-forming cells assay performed in the patient showed residual clonogenic capability, increased in vitro by addition of protease inhibitors and IL-2. A new therapeutic scheme including darunavir and maraviroc allowed dramatic changes leading both to a quick reduction in plasmatic viral load with an impressive immune reconstitution and an improvement in clinical conditions.
- Published
- 2009
307. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
- Author
-
Isgrò A, Leti W, De Santis W, Marziali M, Esposito A, Fimiani C, Luzi G, Pinti M, Cossarizza A, Aiuti F, and Mezzaroma I
- Subjects
- Adult, Aged, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Fas Ligand Protein biosynthesis, Female, HIV Infections drug therapy, HIV-1 drug effects, Hematopoietic Stem Cells, Humans, Interleukin-2 biosynthesis, Interleukin-7 biosynthesis, Male, Middle Aged, RNA, Viral blood, Stromal Cells immunology, Tumor Necrosis Factor-alpha biosynthesis, fas Receptor biosynthesis, Bone Marrow immunology, CD4-Positive T-Lymphocytes immunology, HIV Infections immunology, HIV Infections virology, Lymphopoiesis immunology, Viral Load
- Abstract
Background: Inflammatory cytokines in bone marrow may impair hematolymphopoiesis in human immunodeficiency virus (HIV)-infected subjects who do not experience reconstitution of CD4(+) T cells despite suppression of virus replication while receiving highly active antiretroviral therapy (HAART) (immunological nonresponders)., Methods: Bone marrow samples from 12 immunological nonresponders receiving HAART were studied and compared with samples from 11 immunological responders. The mean CD4(+) T cell count (+/- standard deviation) was 174 +/- 68 cells/mm(3) and plasma HIV RNA levels had been <50 copies/mL for at least 1 year for individuals enrolled in the study. The clonogenic capability of bone marrow samples was evaluated using the colony forming cell assay and the long-term culture-initiating cell assay. CD34(+) cells from the colony forming cell assay were pooled for real-time polymerase chain reaction analysis of Fas and Fas ligand. Bone marrow cytokine production (interleukin-2 and tumor necrosis factor-alpha) and stromal interleukin-7 levels were analyzed by enzyme-linked immunosorbent assay in both groups. Flow cytometric analysis of CD4(+) and CD8(+) T cell subsets was performed., Results: A reduced clonogenic capability and a decrease in the level of more primitive progenitor cells were observed in parallel with lower production of interleukin-2 and increased tumor necrosis factor-alpha levels. A significant upregulation of Fas and Fas ligand on CD34(+) cells and a higher stromal interleukin-7 production were observed. Impairment of the naive T cell compartment and persistent T cell activation were observed in peripheral blood., Conclusions: Samples from immunological nonresponders show reduced growth of in vitro colonies and an altered cytokine production in bone marrow. The cytokine pattern observed and the altered Fas and Fas ligand pathway may determine stem cell apoptosis and low CD4(+) cell recovery. These features, which are similar to those observed in HIV-infected subjects before starting therapy, persist despite treatment.
- Published
- 2008
- Full Text
- View/download PDF
308. T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART.
- Author
-
Marziali M, De Santis W, Carello R, Leti W, Esposito A, Isgrò A, Fimiani C, Sirianni MC, Mezzaroma I, and Aiuti F
- Subjects
- Adult, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Female, Flow Cytometry, HIV Infections drug therapy, HIV Infections virology, Homeostasis immunology, Humans, Immunophenotyping, Interleukin-7 blood, Male, Middle Aged, Receptors, Antigen, T-Cell, alpha-beta blood, Receptors, Interleukin-7 blood, T-Lymphocyte Subsets immunology, Viral Load, HIV Infections immunology, HIV-1
- Abstract
Objective: To investigate the pathogenesis of low CD4 T-cell count in subjects who are immunological non responders (InR) to HAART., Design: Thirty-five HIV-positive subjects on HAART for at least 1 year, all with undetectable HIV-1 RNA, were studied. Patients were defined as InR according to a CD4 cell increase < 20% from CD4 cell baseline or CD4 cell count < 200/microl; subjects with a CD4 T-cell increase > 20% from baseline and a CD4 cell count > 200/microl were defined as immunological responders (IR). We performed a comprehensive study to characterize the immune response of InR., Methods: The immunological phenotype of peripheral blood mononuclear cells, thymic naive T cells, T-cell receptor Vbeta repertoire, serum concentration of interleukin (IL)-7, the expression of IL-7Ralpha on naive and memory CD4 and CD8 T cells, and regulatory T cells (Treg) were studied., Results: In InR a significant reduction (P < 0.0001) of naive and thymic naive CD4 T cells was associated with a reduced expression of IL-7Ralpha in both cell subsets, with an increased serum concentration of IL-7 was observed. Furthermore, an increased immune activation with a reduced Treg frequency and increased number of expansions of Vbeta families was observed., Conclusions: The reduced expression of IL-7Ralpha associated with the persistent immune activation and the alteration of Treg frequencies in part explains the low level of CD4 T cells observed in InR.
- Published
- 2006
- Full Text
- View/download PDF
309. Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study.
- Author
-
Gianotti N, Mondino V, Rossi MC, Chiesa E, Mezzaroma I, Ladisa N, Guaraldi G, Torti C, Tarquini P, Castelli P, Di Carlo A, Boeri E, Keulen W, Kenna PM, and Lazzarin A
- Subjects
- Adult, Antiretroviral Therapy, Highly Active, Female, Genotype, HIV Protease Inhibitors therapeutic use, Humans, Italy, Male, Middle Aged, Phenotype, RNA, Viral blood, RNA, Viral genetics, Reverse Transcriptase Inhibitors therapeutic use, Viral Load, Algorithms, Anti-HIV Agents therapeutic use, HIV genetics, HIV Infections drug therapy, Mutation, Salvage Therapy
- Abstract
Background: There is still considerable uncertainty as to the best algorithm for interpreting human immunodeficiency virus (HIV) genotyping results., Methods: A total of 318 subjects with HIV RNA levels of >1000 copies/mL were enrolled in 41 centers throughout Italy from 2001 through 2003, stratified on the basis of their drug history, randomized (1:1) to 2 arms to have their treatments modified on the basis of the results of HIV genotyping (as interpreted by virtual phenotype analysis or with use of a rule-based interpretation system), and followed up for 48 weeks. At least 1 nucleoside reverse-transcriptase inhibitor and 1 protease inhibitor had to be included in any new regimen; nonnucleoside reverse-transcriptase inhibitor-naive patients were also prescribed a nonnucleoside reverse-transcriptase inhibitor. Only drugs licensed in Italy were allowed. The primary end point was a decrease in HIV RNA level to <400 copies/mL by week 12 according to on-treatment analysis., Results: The mean (+/- standard deviation) values at baseline were as follows: HIV RNA level, 4.1+/-0.74 log(10) copies/mL; CD4(+) T lymphocyte count, 410+/-262 cells/microL; reverse-transcriptase mutations, 4.8+/-2.9; and protease mutations, 2.8+/-2.5. There were 133 patients (41.8%) who were nonnucleoside reverse-transcriptase inhibitor naive and protease inhibitor experienced, 63 patients (19.8%) who were nonnucleoside reverse-transcriptase inhibitor experienced and protease inhibitor naive, and 122 patients (38.4%) who were 3-class experienced. A total of 192 patients completed 12 weeks of the treatment regimen assigned at baseline; at 12 weeks, 66.3% of patients in the virtual phenotype arm and 71.3% of patients in the rule-based interpretation arm had HIV RNA levels of <400 copies/mL (P = .46). No statistically significant difference between arms was observed by intention-to-treat analysis., Conclusion: Both the virtual phenotype and rule-based interpretation methods of HIV genotyping can guide the selection of effective antiretroviral drugs for a salvage regimen.
- Published
- 2006
- Full Text
- View/download PDF
310. Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART.
- Author
-
Aiuti F and Mezzaroma I
- Subjects
- HIV Infections virology, HIV-1 physiology, Humans, Virus Replication drug effects, Antiretroviral Therapy, Highly Active, CD4-Positive T-Lymphocytes immunology, HIV Infections drug therapy, HIV Infections immunology, HIV-1 drug effects
- Abstract
HAART in HIV-1-infected individuals has a broad spectrum of clinical outcomes. In the majority of patients, plasma viral load becomes undetectable and CD4+ T-cells increase over time. However, in a number of subjects a discrepancy between plasma viral load and the CD4+ T-cell recovery is observed. CD4+ T-cell count can rise despite persistently detectable plasma viral load (virologic nonresponders), or conversely does not increase despite full plasma viral load suppression (immunologic nonresponder). Defective immune reconstitution may depend on several factors including previous therapeutic failure, duration of antiretroviral therapy, low CD4+ T-cell count at the initiation of HAART, advanced stage of disease, low adherence to HAART, and previous treatment interruption. There is no definitive evidence that age, viral strain/clade, or host genetic factors play a role in these different responses to HAART. The roles of T-cell subsets, thymic function, and cytokines have been investigated. The increased T-cell activation/apoptosis has been associated with a lack of effective immunologic response. Unabated virologic replication in lymphoid tissues, despite undetectable plasma viral load, has been proposed as the underlying mechanism of cellular activation. However, this "paradoxical response" probably can be associated with other events. Insufficient CD4+ T-cell repopulation of lymphoid tissues may be due to a thymus failure or a defect in bone marrow function. Lifelong infection, the toxic effect of antiviral drugs on T- and B-cell precursors, the stage of disease, and the low number of CD4+ T-cells before HAART may also account for thymus exhaustion and insufficient T-cell renewal. Finally, an imbalance in the production of cytokines such as TNF, IL-2 and IL-7 may also be a crucial event for the induction of immune system failure. In patients in which CD4+ T-cells are not increased by HAART, therapeutic strategies aimed at increasing these cells and reducing the risk of infections are needed. IL-2 and/or other cytokines may be of benefit in this setting. Some antiviral drugs may be better than others in immunologic reconstitution. Protease inhibitors may have additional, independent positive effects on the immune system. On the other hand, there may be little rationale for using immunosuppressive agents such as cyclosporine or hydroxyurea in this subgroup of immunologic nonresponder patients, as these molecules may increase T-cell decline and/or favor susceptibility to infections.
- Published
- 2006
311. Decreased apoptosis of bone marrow progenitor cells in HIV-1-infected patients during highly active antiretroviral therapy.
- Author
-
Isgrò A, Mezzaroma I, Aiuti A, Fantauzzi A, Pinti M, Cossarizza A, and Aiuti F
- Subjects
- Anti-HIV Agents therapeutic use, Antiretroviral Therapy, Highly Active, Apoptosis, HIV Infections drug therapy, HIV Infections immunology, Hematopoietic Stem Cells immunology, Humans, fas Receptor analysis, HIV Infections pathology, HIV-1, Hematopoietic Stem Cells pathology
- Abstract
Impaired haematopoiesis during HIV-1 infection may be caused by the overproduction of inflammatory cytokines by immune cells at the bone marrow level inducing Fas-mediated apoptosis of stem progenitors. In this study, we evaluated the effects of highly active antiretroviral therapy on apoptosis of CD34+ stem cells derived from the bone marrow of HIV-1-infected patients, and observed decreased Fas expression on progenitor cells, in parallel with the diminution of TNF-alpha levels and the amelioration of clonogenic parameters.
- Published
- 2004
- Full Text
- View/download PDF
312. Interleukin 7 production by bone marrow-derived stromal cells in HIV-1-infected patients during highly active antiretroviral therapy.
- Author
-
Isgrò A, Aiuti F, Mezzaroma I, Franchi F, Mazzone AM, Lebba F, and Aiuti A
- Subjects
- CD4 Lymphocyte Count, HIV Infections drug therapy, Humans, Lymphopenia virology, Stromal Cells metabolism, Antiretroviral Therapy, Highly Active methods, Bone Marrow Cells metabolism, HIV Infections metabolism, Interleukin-7 biosynthesis
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.